Tumor clearance of technetium 99m-sestamibi as a predictor of response to neoadjuvant chemotherapy for locally advanced breast cancer.
作者： A Ciarmiello , S Del Vecchio , P Silvestro , M I Potena , M V Carriero
DOI: 10.1200/JCO.1998.16.5.1677
关键词:
摘要: PURPOSESince we have previously shown that the efflux rate of technetium 99m (99mTc) sestamibi, a transport substrate P-glycoprotein (Pgp), is directly correlated with Pgp levels in untreated breast carcinoma, tested whether tumor clearance 9mTc-sestamibi may be predictive therapeutic response to neoadjuvant chemotherapy patients locally advanced cancer.PATIENTS AND METHODSThirty-nine stage III disease, median diameter 5.8 cm (range, 3 10) were enrolled onto this prospective clinical trial and underwent 99mTc-sestamibi scan before chemotherapy. Patients injected intravenously (i.v.) 740 MBq 99mTc-sestamibi; 15-minute dynamic study was performed, static planar images obtained at 0.5, 1, 2, 4 hours. The time half calculated each patient from decay corrected time-activity curves using monoexponential fitting. treated epirubicin 150 mg/m2 i.v. every 2 weeks for ...
elsevier.com
sci-hub.se 参考文章(25)
R. S. Weinstein, K. K. Hansen, R. B. McBeath, W. S. Dalton, Expression of the MDR1 gene (P-glycoprotein) in breast cancer. Recent results in cancer research. ,vol. 127, pp. 49- 54 ,(1993) , 10.1007/978-3-642-84745-5_7
AJ Minn, CM Rudin, LH Boise, CB Thompson, Expression of Bcl-xL Can Confer a Multidrug Resistance Phenotype Blood. ,vol. 86, pp. 1903- 1910 ,(1995) , 10.1182/BLOOD.V86.5.1903.BLOODJOURNAL8651903
Khew-Voon Chin, Ira Pastan, Michael M. Gottesman, Function and Regulation of the Human Multidrug Resistance Gene Advances in Cancer Research. ,vol. 60, pp. 157- 180 ,(1992) , 10.1016/S0065-230X(08)60825-8
Biray Caner, Mustafa Unlü, Günaydin Erbengi, Tamer Çalikoğlu, Mehmet Kitapçl, Coşkun Bekdik, Talat Göğüş, Technetium-99m-MIBI uptake in benign and malignant bone lesions: a comparative study with technetium-99m-MDP. The Journal of Nuclear Medicine. ,vol. 33, pp. 319- 324 ,(1992)
T Habeshaw, J Paul, R Jones, S Stallard, M Stewart, S B Kaye, M Soukop, R P Symonds, N S Reed, E M Rankin, Epirubicin at two dose levels with prednisolone as treatment for advanced breast cancer: the results of a randomized trial. Journal of Clinical Oncology. ,vol. 9, pp. 295- 304 ,(1991) , 10.1200/JCO.1991.9.2.295
F. Thiebaut, T. Tsuruo, H. Hamada, M. M. Gottesman, I. Pastan, M. C. Willingham, Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues Proceedings of the National Academy of Sciences of the United States of America. ,vol. 84, pp. 7735- 7738 ,(1987) , 10.1073/PNAS.84.21.7735
I M HASSAN, A SAHWEIL, C CONSTANTINIDES, A MAHMOUD, M NAIR, Y T OMAR, H M ABDEL-DAYEM, Uptake and kinetics of Tc-99m hexakis 2-methoxy isobutyl isonitrile in benign and malignant lesions in the lungs. Clinical Nuclear Medicine. ,vol. 14, pp. 333- 340 ,(1989) , 10.1097/00003072-198905000-00005
Turid Aas, Anne-Lise Børresen, Stephanie Geisler, Birgitte Smith-Sørensen, Hilde Johnsen, Jan E. Varhaug, Lars A. Akslen, Per E. Lønning, Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients Nature Medicine. ,vol. 2, pp. 811- 814 ,(1996) , 10.1038/NM0796-811
Miguel A Valverde, Mario DÍaz, Francisco V Sepúlveda, Deborah R Gill, Stephen C Hyde, Christopher F Higgins, None, Volume-regulated chloride channels associated with the human multidrug-resistance P-glycoprotein. Nature. ,vol. 355, pp. 830- 833 ,(1992) , 10.1038/355830A0
J. L. Moretti, M. Caglar, C. Boaziz, N. Caillat-Vigneron, J. F. Morere, Sequential functional imaging with technetium-99m hexakis-2-methoxyisobutylisonitrile and indium-111 octreotide: can we predict the response to chemotherapy in small cell lung cancer? European Journal of Nuclear Medicine and Molecular Imaging. ,vol. 22, pp. 177- 180 ,(1995) , 10.1007/BF00838949